CASI Pharmaceuticals income statement data for the quarter ended Jun 2026. This income statement covers 18 quarters of results from Dec 2021 through Jun 2026, standardized by Business Quant from the company’s SEC filings.
| Income StatementIncome Statement | Dec2021 | Mar2022 | Jun2022 | Sep2022 | Dec2022 | Mar2023 | Jun2023 | Sep2023 | Dec2023 | Mar2024 | Jun2024 | Sep2024 | Dec2024 | Mar2025 | Jun2025 | Sep2025 | Dec2025 | Jun2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue & cost | ||||||||||||||||||
| Revenue | 9.06M | 8.57M | 10.21M | 15.26M | 8.35M | 9.82M | 8.84M | 6.87M | 3.41M | 3.98M | 7.79M | 13.36M | 6.24M | 4.18M | 3.08M | 7.22M | ||
| Cost of RevenueCost of Rev | 3.76M | 3.55M | 4.25M | 4.27M | 3.38M | 3.99M | 3.65M | 2.82M | 1.60M | 1.91M | 3.75M | 10.13M | 2.62M | 2.12M | 2.37M | 3.53M | ||
| Gross Profit | 5.30M | 5.02M | 5.97M | 10.99M | 4.97M | 5.83M | 5.19M | 4.06M | 1.81M | 2.07M | 4.05M | 3.23M | 3.62M | 2.06M | 0.71M | 3.69M | ||
| Operating items | ||||||||||||||||||
| Research & DevelopmentR&D | 3.99M | 3.85M | 3.91M | 4.25M | 2.53M | 2.61M | 2.40M | 2.31M | 2.48M | 1.25M | 1.52M | 3.67M | 1.94M | 1.72M | 1.41M | 1.24M | ||
| Selling, General & AdministrativeSG&A | 5.33M | 5.52M | 4.85M | 7.76M | 5.75M | 7.70M | 5.52M | 6.42M | 4.81M | 5.94M | 5.70M | 7.12M | 7.70M | 6.08M | 4.93M | 9.56M | ||
| Other Operating ExpensesOther Opex | 2.94M | 2.04M | 2.93M | 13.95M | 3.90M | 4.86M | 2.37M | 7.67M | 3.97M | 3.66M | 5.29M | 5.36M | 0.01M | 5.38M | 5.04M | 5.72M | ||
| Operating ExpensesOpex | 12.26M | 11.41M | 11.68M | 25.95M | 12.18M | 15.18M | 10.29M | 8.79M | 11.26M | 10.86M | 12.51M | 16.14M | 14.00M | 13.18M | 11.38M | 16.51M | ||
| Operating IncomeOp. Inc | -6.96M | -6.39M | -5.72M | -14.97M | -7.21M | -9.35M | -5.10M | -4.73M | -9.45M | -8.79M | -8.46M | -12.91M | -10.38M | -11.13M | -10.68M | -12.82M | ||
| Non-operating items | ||||||||||||||||||
| Gains (Losses) on Sale of Assets & InvestmentsGains on Sales | -0.14M | -0.17M | 0.50M | 1.20M | -0.27M | |||||||||||||
| Interest & Investment IncomeInt & Inv Inc | 0.13M | 0.14M | 0.14M | 0.13M | 0.08M | 0.05M | 0.01M | 0.00M | ||||||||||
| Other Non Operating IncomeOther Non Op Inc. | 0.04M | 0.01M | 0.01M | 3.23M | 1.34M | 0.01M | 0.47M | 0.45M | 0.16M | 0.27M | -0.38M | 0.35M | 0.02M | -0.42M | -0.43M | -1.15M | ||
| Net income details | ||||||||||||||||||
| EBIT | -6.96M | -6.39M | -5.72M | -14.97M | -7.21M | -9.35M | -5.10M | -4.73M | -9.45M | -8.79M | -8.46M | -12.91M | -10.38M | -11.13M | -10.68M | -12.82M | ||
| EBT | -6.96M | -6.39M | -5.72M | -14.97M | -7.21M | -9.35M | -5.10M | -4.73M | -9.32M | -8.65M | -8.32M | -12.78M | -10.30M | -11.08M | -10.67M | -12.82M | ||
| Tax ProvisionsTaxes | 0.08M | -0.16M | ||||||||||||||||
| Income After Tax | -6.96M | -6.39M | -5.72M | -14.97M | -7.21M | -9.43M | -5.10M | -4.57M | -9.32M | -8.65M | -8.32M | -12.78M | -10.30M | -11.08M | -10.67M | -12.82M | ||
| Equity Income | -8.40M | -7.49M | -5.02M | 20.07M | -5.81M | -0.02M | -0.02M | 0.00M | -9.53M | -1.12M | 9.53M | -10.75M | -2.17M | -0.01M | -0.01M | |||
| Income from Continuing OperationsIncome (Continuing) | -6.96M | -6.39M | -5.72M | -14.97M | -7.21M | -9.43M | -5.10M | -4.57M | -9.32M | -8.65M | -8.32M | -12.78M | -10.30M | -11.08M | -10.67M | -12.82M | ||
| Consolidated Net IncomeConsol Net Inc. | -8.15M | -11.03M | -8.15M | -12.92M | -5.63M | -12.25M | -4.64M | -3.74M | -9.43M | -7.28M | -8.44M | -14.10M | -11.20M | -13.39M | -10.91M | -12.59M | ||
| Net Income Attributable to Noncontrolling InterestsNCI Net Income | -0.34M | -1.80M | -2.07M | -6.38M | -0.56M | -1.79M | -0.75M | -0.13M | ||||||||||
| Income towards Parent CompanyParent Net Inc | -8.40M | -7.49M | -5.02M | -20.10M | -5.83M | -10.07M | -4.47M | -6.59M | -9.53M | -6.97M | -8.40M | -14.37M | -10.75M | -13.38M | -10.88M | -13.04M | ||
| Preferred Dividend PaymentsPref Dividends | 0.61M | 0.74M | 0.92M | 7.23M | 0.85M | 0.76M | 0.77M | 0.91M | ||||||||||
| Net Income towards Common StockholdersNet Income | -9.01M | -9.23M | -6.08M | -27.33M | -6.68M | -10.46M | -5.24M | -7.50M | -9.43M | -7.28M | -8.44M | -14.68M | -10.75M | -13.39M | -10.91M | -12.56M | ||
| Additional items | ||||||||||||||||||
| EPS (Basic) | -0.66 | -0.68 | -0.45 | -2.00 | -0.49 | -0.77 | -0.38 | -0.56 | -0.71 | -0.54 | -0.63 | -0.96 | -0.70 | -0.87 | -0.71 | -0.68 | ||
| EPS (Diluted) | -0.66 | -0.68 | -0.45 | -2.00 | -0.49 | -0.77 | -0.38 | -0.56 | -0.71 | -0.54 | -0.63 | -0.96 | -0.70 | -0.87 | -0.71 | -0.68 | ||
| Shares Outstanding | 13.61M | 13.61M | 13.61M | 13.61M | 13.65M | 13.65M | 13.65M | 13.65M | 13.36M | 13.36M | 13.36M | 13.36M | 15.34M | 15.34M | 15.34M | 15.34M | 18.54M | 18.54M |
| Shares Outstanding (Diluted)Shares Outstanding (Dil.) | 13.61M | 13.61M | 13.61M | 13.61M | 13.65M | 13.65M | 13.65M | 13.65M | 13.36M | 13.36M | 13.36M | 13.36M | 15.34M | 15.34M | 15.34M | 15.34M | 18.54M | 18.54M |
| Shares Outstanding (Entity)Shares Outstanding (Entity.) | 13.98M | 13.46M | 13.38M | 15.49M | 20.56M |
Pull CASI Pharmaceuticals's standardized financial statements into your own models, spreadsheets and apps with the Business Quant Financial Statements API. The request below follows the statement, frequency and period selected above. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/statements?ticker=CASIF&statement=IS&frequency=Quarter&period=all&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/statements"
params = {"ticker": "CASIF", "statement": "IS", "frequency": "Quarter", "period": "all", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/statements?ticker=CASIF&statement=IS&frequency=Quarter&period=all&api_key=YOUR_API_KEY");
const data = await res.json();